1

# Immunosenescence profile is associated with increased susceptibility to severe COVID-19

Lucas Haniel A. Ventura<sup>1#</sup>, Lícia Torres<sup>1#</sup>, Giovanna Caliman Camatta<sup>1</sup>, Jofer 3 Zamame<sup>2</sup>, Monique Macedo Coelho<sup>1</sup>, Cecília Horta Ramalho-Pinto<sup>1</sup>, João Gervazio<sup>1</sup>, 4 Felipe Caixeta<sup>1</sup>, Leandro Nascimento<sup>1</sup>, Mariana Almeida Oliveira<sup>1</sup>, Vinícius Dantas 5 Martins<sup>1</sup>, Marcos Felipe Oliveira<sup>1</sup>, Murilo Soares da Costa<sup>3</sup>, Hugo Itaru Sato<sup>1</sup>, Henrique 6 Cerqueira Guimarães<sup>4</sup>, Rafael Calvão Barbuto<sup>4</sup>, Ana Paula Rocha Veiga<sup>5</sup>, Najara 7 Ataíde<sup>5</sup>, Gabriela Prandi Caetano<sup>5</sup>, Sarah Rangon<sup>5</sup>, Mauro Lúcio O. Júnior<sup>6</sup>, Fernanda 8 Calvo Fortes<sup>1</sup>, Luciana Zuccherato<sup>1</sup>, Elaine Speziali<sup>7,8</sup>, Olindo Assis Martins-Filho<sup>7</sup>, 9 Verônica Coelho<sup>9</sup>, Roberto Avritchir<sup>10</sup>, Rafael Souza<sup>5</sup>, Marina Ayupe<sup>2</sup>, Caio Loureiro<sup>2</sup>, 10 Maria Eduarda Passos<sup>11</sup>, Ana Clara Mota Neves<sup>11</sup>, Pauline Leite<sup>11</sup>, Santuza Maria 11 Ribeiro Teixeira<sup>1</sup>, Unaí Tupinambas<sup>3</sup>, Liza Figueiredo Felicori<sup>1</sup>, Gabriela Silveira-12 Nunes<sup>11</sup>, Tatiani Uceli Maioli<sup>1,12</sup>, Denise Morais Fonseca<sup>2</sup>, Andrea Teixeira-Carvalho<sup>7</sup>, 13 Ana Maria Caetano Faria<sup>1\*</sup> 14

15

- <sup>1</sup> Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de
   Minas Gerais, Belo Horizonte, Brazil
- 18 <sup>2</sup> Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, Brazil
- <sup>3</sup> Departamento de Doenças Tropicais e Infecciosas, Faculdade de Medicina, Universidade Federal de
   Minas Gerais, Belo Horizonte, Brazil
- <sup>4</sup> Hospital Risoleta Tolentino Neves, Belo Horizonte, Brazil.
- <sup>5</sup> Instituto de Infectologia do Hospital Emílio Ribas, São Paulo, Brazil.
- <sup>6</sup> Hospital da UNIMED, Governador Valadares, Brazil
- 24 <sup>7</sup> Instituto de Pesquisa René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil
- <sup>8</sup> Universidade Edson Antônio Velano, Fundação de Ensino e Tecnologia de Alfenas, Belo Horizonte,
   Brazil.
- 27 <sup>9</sup> Instituto do Coração, Universidade de São Paulo, São Paulo, Brazil.
- 28 <sup>10</sup> Santa Casa de Misericórdia, São Paulo, Brazil.
- <sup>11</sup> Departamento de Medicina, Universidade Federal de Juiz de Fora, Governador Valadares, Brazil
- <sup>12</sup> Departamento de Nutrição, Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo
   Horizonte, Brazil
- 32
- 33 # These authors contributed equally to this study.

\*Corresponding Author: Ana Maria Caetano Faria, Departamento de Bioquímica e Imunologia,
 Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Belo

36 Horizonte, CEP 31270-901, MG, Brazil. E-mail: <u>anacaetanofaria@gmail.com</u>

- Key words: Immunosenescence, Inflammaging, COVID-19, Immunoglobulin
   repertoire, T cell senescence, T cell exhaustion, epigenetic clock
- 40

## 41 Abstract:

42 In this study we tested the hypothesis that the immunosenescence profile could account 43 for the disproportional susceptibility of the elderly to severe forms of COVID-19. The immunological profiles of volunteers residing in endemic and non-endemic areas for 44 chronic infectious diseases were analyzed at early stage of SARS-CoV-2 infection. A 45 unique signature of inflammatory plasma mediators was identified in COVID-19 46 volunteers when compared to individuals with other flu-like syndromes. COVID-19 47 48 severity correlated with high levels of inflammatory mediators; among them, CXCL9, a serum marker of aging. Patients who progressed to hospitalization displayed high 49 frequencies of CD8<sup>+</sup> and CD4<sup>+</sup> T cells expressing exhaustion and senescence markers 50 and showed reduced and more mature B cell repertoires, which are typical of 51 senescence. They also had an acceleration of epigenetic age measured by DNA 52 53 methylation. Therefore, severe COVID-19 correlated with phenotypic, functional, and 54 epigenetic features of accelerated immunosenescence at onset of infection.

# 55 Introduction:

56

57 Since the onset of COVID-19 cases, the elderly have been the main risk group 58 for severe disease worldwide. This pattern of susceptibility was reported initially in 59 China<sup>1</sup>, Italy<sup>2</sup> and later in several countries including Brazil<sup>3</sup>.

SARS-CoV-2 infection is cleared by a normal anti-viral response in most 60 61 individuals, but some progress to a hyperinflammatory condition, often with severe 62 pulmonary involvement. It has been shown that 5–6% of these patients need mechanical 63 ventilation due to respiratory failure developed by lung and microcirculation damage, with profound hypoxia, severe acute respiratory syndrome (SARS) and multiple organ 64 dysfunction. These individuals have systemic hyperinflammation with classical serum 65 biomarkers of "cytokine storm syndrome" including abnormal coagulation, elevated C 66 67 reactive protein (CRP), LDH, ferritin, IL-1β, TNF, IL-6, IFN-γ, IL-10, IL-15, IL-2, IL-5, CCL2, CCL3, CCL4 and CXCL10<sup>4</sup>. Therefore, uncontrolled inflammation is clearly 68 associated with severe life-threatening COVID-19. Interestingly, many of these 69 mediators are the ones found to induce a low-grade chronic state of inflammation 70 known as inflammaging and originated from senescent cells, cumulative stimulation of 71 immune cells and lifestyle risk factors <sup>5,6</sup>. 72

Aging affects all body compartments, but the immune system is particularly 73 impacted. Immunosenescence is associated with a decline in the production and activity 74 of T and B cells, many defects in innate immune cells, and thymic atrophy. The 75 progressive reduction in the output of naïve T cells from the thymus creates an 76 77 oligoclonal repertoire of expanded subsets of memory T cells and exhausted/senescent lymphocytes (mostly CD8 T cells) with low proliferative capacity. At the same time, 78 79 senescent immune and non-immune cells develop a secretory phenotype (SASP) that includes innate cytokines and chemokines such as CXCL8, IL-6, IL-18, TNF and IL-18 80 responsible for the development of the inflammaging<sup>6</sup>. Immunosenescence is also 81 associated with a reduction in production of B cells by the bone marrow. This decline in 82 T/B cell production leads to the peripheral accumulation of cells with an exhausted 83 repertoire displaying lower diversity of T/B cell receptors <sup>7,8</sup>, and poor responses to 84 infectious agents and vaccines <sup>6,9,10</sup>. Thus, response to a virus infection such as SARS-85 86 CoV-2 in the elderly can be very abnormal as already observed for other viruses<sup>11</sup>.

4

Interestingly, not all elderly developed the severe form of COVID-19<sup>12</sup> and not 87 all aged individuals have a dysfunctional immunological profile. Studies on healthy 88 nonagenarians and centenarians in Italy and on healthy elderly people in Brazil showed 89 90 that these individuals develop remodelling mechanisms to control the deleterious effects of inflammation and immunosenescence <sup>6,13–15</sup>. On the other hand, our group have 91 shown that individuals living in endemic areas for infectious diseases (such as 92 93 Schistosomiasis, Leishmaniasis, Leprosy, Chagas Disease, Dengue, Chikungunya, Yellow Fever) exhibit an accelerated biological age as measured by DNA methylation<sup>16</sup> 94 with an unique immunological profile<sup>14,17-20</sup>. Therefore, aging does not affect 95 individuals homogeneously and the resulting senescence phenotype seems to be 96 97 determined by genetic, epigenetic and biographical factors related to the interactions of 98 the immune system and the body with its environment.

99 Our hypothesis in this study is that the immunosenescence profile, rather than 100 the chronological age, will impact on the development of the inflammatory damage seen 101 in severe COVID-19 by creating a permissive environment for a dysfunctional response 102 to the virus. Moreover, it is likely that factors such as chronic antigenic exposure in 103 endemic areas for infectious diseases would enhance a preexisting immunosenescence 104 phenotype.

105 Although some authors have theoretically proposed an association between 106 COVID-19 severity and senescence biomarkers such as inflammaging, biological 107 clocks, mTOR activity, and telomer shortening <sup>21–24</sup>, only few studies have 108 experimentally addressed this proposal using only cohorts of hospitalized individuals at 109 heterogeneous time points of infection with mixed results <sup>25,26</sup>.

110 Several distinctive parameters were used in this study to reach non-ambiguous conclusions when testing our hypothesis: (i) we investigated individuals from three 111 112 cities in Brazil with distinct patterns of biological aging; (ii) our cohort had only 113 individuals at early stage of infection (1-4 days of symptoms) to avoid confusion between the impact of immunosenescence in COVID-19 outcome with accelerated 114 immunosenescence induced by SARS-CoV-2 infection itself<sup>27</sup>; (iii) a group of 115 individuals with flu-like symptoms but negative for SARS-CoV-2 infection was 116 included as a control to distinguish COVID-19 from other airway viral infections; (iv) 117 all individuals were clinically followed for 14 days to monitor disease progression, 118 sometimes from mild to severe, as in the case of a specific group of patients 119

5

(progression group); (v) four parameters were tested to make up the immunosenescence
profile - plasma mediators to examine the inflammaging, phenotypical biomarkers of
memory, exhaustion and senescence in T cells, diversity and maturity of B cell
repertoires and the epigenetic age of the individuals.

124

125 **Results** 

126

# Severe COVID-19 associated with a high inflammatory profile at early stage ofinfection.

129 The main features of our study population are shown in **Table 1** and **2**. For all the analysis reported below, individuals in each group were matched by age, sex and 130 number of comorbidities. We only included in the analysis individuals at early stage of 131 infection (1-4 days of symptoms). Other factors that could interfere with the 132 133 interpretation of our data were also controlled. (i) There was no significant difference in 134 the body mass index (BMI) among the groups that could contribute as an inflammatory stimulus to the distinct outcomes <sup>28</sup>. (ii) The presence of comorbidities was a general 135 feature of our cohort, and the most reported ones were hypertension, diabetes mellitus, 136 and respiratory diseases. Since they are inflammatory conditions that could interfere 137 with COVID-19 severity <sup>29</sup>, all groups analysed in this study were matched by the 138 139 presence of an equal number of comorbidities (considered as equivalent conditions). 140 (iii) To exclude the possibility that disease outcome would be related to differences in viral load as already reported for other infections by virus such as influenza <sup>30</sup> and 141 adenovirus <sup>31</sup>, concentration values for SARS-CoV-2 ribonucleic acid in each swab 142 143 sample were calculate and compared among clinical groups. We used cycle threshold (Ct) values as a surrogate for viral load given the already reported linear correlation 144 between Ct values and viral concentration down to the limit of detection<sup>32</sup>. 145 **Supplementary Figure 1a** shows that individuals with mild, moderate, and severe 146 147 COVID-19 presented comparable CT values indicating that disease outcome was not due to the abundance of virus in the respiratory tract. (iv) Individuals previously 148 149 infected by SARS-CoV-2 were identified by serology (using Bio-Plex Multiplex SARS-CoV-2 Serology Assay Kit) and excluded from the study. (v) Since a high prevalence of 150 Vitamin D deficiency has been reported to correlate with increased morbidity and 151 mortality related to COVID-19 infection<sup>33</sup>, serum levels of vitamin D were measured in 152

6

individuals of our cohort. No significant difference among the clinical groups of
COVID-19 was observed (Supplementary Figure 1b) ruling out the possible influence
of its deficiency in the outcome of the disease.

Since previous studies have shown that inflammaging is a hallmark of 156 immunosenescence<sup>10</sup>, we first characterized the inflammatory profile of the individuals 157 in all groups using a Luminex-Multiplex assay for 27 immune mediators. For this first 158 analysis, the study population was segregated into five groups: Flu-like Syndrome 159 160 (FLS) group comprising individuals who were negative for SARS-CoV-2 and had an unknown mild respiratory infection, Mild, Moderate and Severe COVID-19 groups 161 according to WHO classification guidelines<sup>34</sup> (Supplementary Table 1). The fifth 162 group (Progression) consisted of individuals who were classified as Mild COVID-19 at 163 164 recruitment but progressed to severe disease with hospitalization during the 14-day 165 follow-up period.

A radar chart showing a global analysis of plasma mediators produced by 166 individuals with mild, moderate, and severe COVID-19 shows that, at early stage of 167 168 infection, disease severity was already positively correlated with the frequency of high producers of several inflammatory mediators (Figure 1a). Among these mediators, we 169 170 identified 10 that were significantly different among the groups (Figure 1b): CCL2, 171 CXCL8, CXCL10, IL-1β, IL-6, TNF, IFN-gamma, IL-12p70, IL-1Ra, IL-10. These are classical inflammatory mediators that are part of the inflammaging phenotype <sup>10,35</sup> and 172 were already reported to be at high levels in hospitalized COVID-19 patients. 173 174 Interestingly, the same list of mediators was also significantly higher in individuals with mild COVID-19 when compared to the ones with flu-like syndrome (Figure 1b). 175 176 Although individuals from these two groups shared a spectrum of symptoms and could only be segregated after RT-PCR testing for SARS-CoV-2 infection, they had a distinct 177 inflammatory profile. Mild COVID-19 patients presented a higher global pattern of 178 mediator production (Figure 1c) and several differences in the concentrations of the 10 179 mediators (Figure 1d, Supplementary Figure 2c) since early infection. We also 180 181 observed differences in this inflammatory profile at other time points of disease progression with higher immune activation in mild COVID-19 patients when compared 182 to FLS patients with 5-9 and 10-14 days of symptoms (Supplementary Figure 2 d, e). 183 184 Probably at this stage, immune mediators resulting from the response to infection are at play. Therefore, COVID-19 seems to be related to a unique inflammatory profile when 185

compared to other respiratory viral infections with similar symptoms. Notably, when patients with mild COVID-19 were segregated into adults and elderly, a higher global profile of inflammatory immune activation was detected in aged individuals (**Supplementary Figure 2b, e**) during early stages of infection (1-4 days of symptoms) and later (10-14 days of symptoms) suggesting that inflammaging and the innate immune response triggered by COVID-19 indeed overlap later when immunity to infection is stablished.

193 To help distinguishing between pre-existing inflammaging as a fuel to disease progression and the viral-induced cytokine storm, we studied an important group of 194 195 patients found in our cohort: the progression group. These individuals were classified as having mild symptoms of COVID-19 when they were recruited (1-4 days of symptoms) 196 197 but progressed to severe disease and hospitalization during the 14-day-follow-up period. 198 Notably, the overall inflammatory profile of these patients represented by a radar plot (Figure 1e) and the comparative analysis of the 10 main plasma mediators (Figure 1f) 199 clearly showed that they presented, since the early stages of infection, an inflammatory 200 201 activation similar to the group of severe COVID-19 patients, and significantly different from Mild and FLS patients. This suggests that the initial immunological imprint of 202 203 inflammatory mediators can predict disease outcome.

204

# 205 Severe COVID-19 was associated with higher inflammatory activation in 206 individuals from endemic areas for infectious diseases and with biomarkers of 207 aging.

208 To address the question of how distinct environments influence COVID-19 and 209 whether aging biomarkers can be used to distinguish the different clinical forms of 210 disease, we compared the inflammatory profile of adult and elderly individuals with FS or mild COVID-19 from Belo Horizonte and Governador Valadares, an endemic area 211 212 for several infectious diseases where individuals present an accelerated biological aging <sup>16</sup>. First, we confirmed that there was a clear difference in the global inflammatory 213 214 profiles between individuals with FLS and Mild COVID-19 in the endemic area despite 215 their similarity of symptoms (Figure 2c). Moreover, individuals from Governador 216 Valadares had a higher activation profile when compared to individuals from Belo 217 Horizonte, and the elderly from the endemic area presented a much higher production of

8

immune mediators than adults (Figure 2c). Hence, not only does COVID-19 presented
itself as a greater challenge to the immune system than other respiratory infections, but
the inflammatory activation at early phase of infection is exacerbated in populations
with accelerated biological age.

222 CXCL9 has been recently identified as critical mediator involved in age-related chronic inflammation <sup>36</sup>. Indeed, using this chemokine as a biomarker of aging and 223 frailty, we observed that elderly individuals were higher producers of CXCL9 than 224 225 adults. Interestingly, both adults and elderly hospitalized patients had a similar and 226 more prominent production of this mediator than individuals with FLS or mild COVID-227 19 (Figure 2d). Moreover, elderly individuals presented no difference in CXCL9 228 production across the spectrum of COVID-19 clinical forms (Figure 2e) probably 229 because they already had high baseline levels of this chemokine. Therefore, severe 230 COVID-19 was associated at early stage of infection with increased production of an 231 immunological biomarker of aging.

Our data on the inflammatory profile of individuals from endemic and nonendemic areas in Brazil suggest a strong and unique association between inflammaging at early stages of COVID-19 to disease progression.

235

# Severe COVID-19 correlated with accumulation of memory, exhausted and senescent T cells.

To further explore the association between other features of immunosenescence and COVID-19 outcomes, we investigated changes in the frequencies of T cell populations expressing cell markers of memory, exhaustion, and senescence.

Aging has a great impact in the T cell compartment, especially in CD8<sup>+</sup> T cells Aging has a great impact in the frequencies of functional subsets of T lymphocytes, multiparametric flow cytometry analyses was performed using a panel of monoclonal antibodies to surface markers of exhaustion/senescence in these cells (**Supplementary Table 2**). Gating strategies for all cell populations are shown in **Supplementary Figure** 3.

To investigate immunophenotypes of T lymphocytes, CD4<sup>+</sup> and CD8<sup>+</sup> T cells were studied as global main subpopulations and segregated into functional subsets of

9

249  $(CD45RO^{-}CCR7^{+}).$ effector  $(CD45RO^{-}CCR7^{-}),$ naïve central memory (CD45RO<sup>+</sup>CCR7<sup>+</sup>), effector memory (CD45RO<sup>+</sup>CCR7<sup>-</sup>) T cells. We identify 250 accumulation of several subsets of CD8<sup>+</sup> and CD4<sup>+</sup> T cells expressing markers of 251 exhaustion and senescence in patients with severe COVID-19 (Figure 3). Concerning 252 CD8<sup>+</sup> T cell analysis, individuals with severe disease had higher frequencies of CD8<sup>+</sup> T 253 cells expressing biomarkers of senescence (TIGIT) and exhaustion (ICOS). Effector 254 255  $CD8^+$  T cells expressing PD-1 were also augmented in severe diseased patients (Figure **3 a, b**). In addition, CD8<sup>+</sup> T cells with senescence/ exhaustion phenotypes accumulate in 256 individuals of this group: CD28-PD-1<sup>+</sup>CD57<sup>+</sup>CD8<sup>+</sup>, CD28<sup>+</sup>KLRG1<sup>+</sup>CD8<sup>+</sup>, CD28<sup>-</sup>PD-257 1<sup>+</sup>CD8<sup>+</sup>, CD28<sup>-</sup>KLRG1<sup>+</sup> PD-1<sup>+</sup> CD8<sup>+</sup>, KLRG1<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup>, KLRG1<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup>, 258 TIGIT<sup>+</sup>ICOS<sup>+</sup> CD8<sup>+</sup> and CD28-PD-1<sup>+</sup> effector and effector memory CD8<sup>+</sup> T cells 259 (**Figure 3 c. d**). For  $CD4^+$  T cells, we also found higher frequencies of cells expressing 260 261 the senescence marker TIGIT and of cells expressing the mixed senescence/exhaustion 262 phenotype: TIGIT<sup>+</sup>ICOS<sup>+</sup>CD4<sup>+</sup>, CD28<sup>-</sup>CD57<sup>+</sup>KLRG1<sup>+</sup>CD4<sup>+</sup> and CD28<sup>-</sup>CD57<sup>+</sup>KLRG1<sup>+</sup> effector memory  $CD4^+$  T cells (Figure 3e, f). For some specific sub-populations of 263 senescent (CD4<sup>+</sup>TIGIT<sup>+</sup>) (Figure 3e) and senescent/exhausted (CD28<sup>-</sup>PD-1<sup>+</sup> effector 264 and effector memory CD8<sup>+</sup>, TIGIT<sup>+</sup>ICOS<sup>+</sup>CD4<sup>+</sup>) T cells (Figure 3c), a significant 265 266 difference between patients with mild and moderate disease was observed. Therefore, along with an exuberant inflammaging, COVID-19 patients exhibited an accrual of 267 senescent/exhausted CD8<sup>+</sup> and CD4<sup>+</sup> T cells that make up the scenario of dysfunctional 268 immunity permissive to disease progression. 269

270

# 271 Severity of COVID-19 was associated with a reduction in B cell diversity and 272 higher maturation of the immunoglobulin repertoire.

To study the B cell senescence, we examined the immunoglobulin repertoire in a 273 set of 45 individuals from individuals in Belo Horizonte and Governador Valadares 274 (endemic area) who were either uninfected or tested positive for COVID-19. Within 275 these cities, participants were categorized into negative group (n=6), mild COVID-19 276 277 group (n=19), and hospitalized COVID-19 group (n=20) of individuals from Belo 278 Horizonte and São Paulo along with mild COVID-19 individuals from Governador Valadares. The sequencing resulted in 285,341 to 1,525,890 raw reads. After pre-279 processing, 130,060 to 548,060 annotated reads and 3.053 to 69,737 clones were 280 obtained (Supplementary Table 3). 281

10

Antibody repertoire diversity within the top 100 most expanded clones among 282 283 individuals in Belo Horizonte showed that the Shannon entropy diversity was lower in 284 the hospitalized individuals as compared to both mild COVID-19 and control groups 285 (Figure 4b). Figure 4c also shows that hospitalized individuals had a more mature repertoire with highly mutated VH immunoglobulin genes and lower frequencies of 286 germline-encoded antibodies, a phenotype of an aged repertoire. A graphical 287 288 representation of clonal expansion at day 2 and 7 of symptom onset shows that in both 289 periods the clones from severe individuals are distinct from baseline (negative) and 290 clones from mild individuals (Figure 4a).

291

# Acceleration of biological age was detected in hospitalized individuals with moderate/severe COVID-19

To further explore our hypothesis, we accessed the DNA methylation status of peripheral blood mononuclear cells to investigate whether COVID-19 severity was associated with acceleration of biological age. We used the cohort of individuals that had been already investigated for the inflammatory and phenotypic lymphoid profiles and performed the analysis using different biological age acceleration clocks <sup>16,38</sup>.

299 For this analysis, a negative population was selected as a control. Individuals in this group had no symptoms of infection and were negative for SARS-CoV-2 by RT-300 301 PCR (Table 1). Negative individuals were compared to infected patients with Mild COVID-19 and a Hospitalized COVID-19 group of patients with either moderate or 302 severe clinical disease. Several clocks are now available to access aging acceleration 303 using different gene clusters. We used seven clocks proposed by Horvath<sup>38</sup>, Horvarth 304 Updated, Levine <sup>39</sup>, Hannum <sup>40</sup>, TL <sup>41</sup>, BLUP, EN, Wu <sup>25,42</sup>, to obtain more accuracy in 305 306 detecting acceleration or deceleration of biological age.

Based on data previously published by our group showing that the population of Governador Valadares presents an acceleration of biological age <sup>16</sup>, we decided not to use these individuals in the initial analysis, so that we could focus on understanding the association between age acceleration and disease severity (**Figure 4D**). Notably, individuals of the hospitalized group had an increase in biological age when compared to the mild COVID-19 group (in Horvarth (Updated), Levine, EN, BLUP and TL watches) and to the negative group (in Horvarth, Horvarth (Updated), Hannum, BLUP

11

and EN watches) (Figure 4D). The Wu clock was the only one of the analysed watches
that showed no difference among groups. Next, we analyzed the total population,
including individuals from Governador Valadares, and the result was similar (Figure
4E) except for the TL clock that showed no difference among groups.

Network analysis is a powerful tool for understanding the complex relationships 318 between variables within a system. By constructing a network representation, we can 319 320 visualize and analyze the interconnections between different components. In our study, 321 we employed a weighted network analysis to investigate the correlations between biologically relevant markers associated with cytokines/chemokines and cellular 322 323 proteins that are markers of senescence and exhaustion. Individuals who developed 324 severe COVID-10 had a more connected senescence/exhaustion network than 325 individuals that developed mild COVID-19 (Figure 4F). Among the more connected 326 clusters, senescent and exhausted T cells are dominant. A graphical representation of all data obtained on the senescence profile illustrates the general conclusion that patients 327 with severe disease resemble the aging phenotype (Figure 4G). 328

Therefore, our data clearly correlate several features of the immunosenescence profile including inflammaging, increased frequencies of senescent/exhausted T cells, oligoclonality of B cell repertoire and finally an acceleration of biological age suggesting that this dysfunctional immune profile can explain, at least in part, the high susceptibility of aged people to develop severe forms of COVID-19.

334

# 335 Discussion

Since the beginning of the SARS-CoV-2 pandemic, the elderly have been the 336 main risk group for the mortality and the severe clinical outcomes of COVID-19<sup>2</sup>. 337 338 Several review articles have proposed that remodelling features acquired by the aging 339 immune system such as the inflammaging phenomenon and dysfunctional immunity might have a major role in the unfavourable outcome of the disease in older individuals 340 <sup>4,21-24,43</sup>. Besides these theoretical proposals, some studies have addressed the 341 342 hypothesis in experiments using senolytics in aged mice infected with a SARS-CoV-2related virus<sup>44</sup> and in individuals with severe and critically ill COVID-19 patients by 343 analyzing exhausted/senescent T cells <sup>45,46</sup> and age-acceleration clocks <sup>25</sup>. 344

12

345 In our study, we used more than one approach to reach a reliable conclusion when testing our hypothesis, we distinguish patients with mild disease from those 346 severely ill to investigate the effect of aging phenotype in the disease outcome and we 347 348 specifically restrict our sample to early infected patients (1-4 days of symptoms), a period when senescent and exhausted T cells are at baseline frequencies (a small 349 percentage of the overall cell population) in mild COVID-19<sup>27</sup>. Our group and others 350 have shown that SARS-CoV-2 infection induces not only a systemic inflammatory 351 response similar to the inflammaging<sup>47</sup> but it also leads to the emergence of exhausted 352 and senescent T cells after a period of infection as short as 7 days  $^{27,45}$ . In addition, we 353 included volunteers with mild flu-like symptoms who tested negative for SARS-CoV-2 354 355 as a control since these individuals did not show accumulation of exhausted/senescent cells even after 7 days of infection. At this stage, there is probably an overlap between 356 357 inflammaging and innate cytokines/ chemokines produced in the early response to SARS-CoV-2<sup>47</sup> because these two responses share a set of mediators including IL-6, 358 CXCL8, C-Reactive Protein (CRP), TNF, IL-1β, IL-10, IL-1Ra IL-12p70, IFN-γ<sup>6,10</sup>. 359

Ten mediators were consistently identified in all COVID-19 patients with 1-4 360 361 days of symptoms, and they were detected at variable levels depending on the clinical form of the disease. Most of them are proinflammatory mediators (CCL2, CXCL8, 362 CXCL10, IL-1 $\beta$ , IL-6, TNF, IFN- $\gamma$ , IL-12p70) that contribute to both frailty in the 363 elderly <sup>10,36,48</sup> and to a series of pathological events seen in COVID-19 such as 364 365 thrombosis of blood capillaries, congestion of the alveolar wall, inflammatory 366 infiltration, formation of hyaline membrane in the alveoli, pulmonary edema, and severe respiratory failure <sup>5,49</sup> whereas others play an anti-inflammatory and regulatory role (IL-367 1Ra and IL-10) in both conditions. Interestingly, even though other viral infections can 368 induce a burst of innate cytokines/chemokines during the first few days of infection <sup>47</sup>, 369 the inflammatory signature observed in individuals with mild COVID-19 and Flu-like 370 371 syndrome in our study were not equivalent (Figure 1c, d, Supplementary Figure 1). 372 This finding underscores the uniqueness of SARS-CoV-2 infection and suggests that the 373 overlap between innate response to the virus and the pre-existing inflammaging 374 phenomenon is of particular importance to COVID-19 with predictive value for the 375 outcome of the disease. A further demonstration of that is the data collected from 376 individuals in the Progression group (Figure 1e, f) that clearly showed an inflammatory 377 signature of severe disease at early stages of infection when symptoms are still mild.

Another distinctive feature of our study population was the inclusion of a group 378 of patients from an endemic region for infectious diseases in Brazil (Governador 379 Valadares, MG). This group allowed us to examine the impact of accelerated 380 imunosenescence and other changes favourable to the senescence process <sup>16,18</sup> in 381 COVID-19 development. Indeed, we found a more prominent inflammatory profile in 382 383 patients from the endemic area even in the mild COVID-19 and flu-like syndrome 384 groups and this hyperactivation was exacerbated in the elderly (Figure 2 a-c, 385 Supplementary Figure 1). These set of results highlight two important aspects 386 concerning infectious diseases. First, it demonstrated that there is a variability of 387 immune responses to a single pathogen, even for those with the same spectrum of symptoms, and this may be determined by genetic and environmental conditions as 388 previously proposed <sup>50</sup>. In addition, it suggests that individuals living in areas of high 389 antigenic burden, despite their accelerated senescence profile <sup>16</sup>, may also develop 390 391 mechanisms of inflammatory remodelling resembling the ones observed in centenarian populations of Italy <sup>6,48</sup> and aged populations in Brazil <sup>17,37</sup>. These mechanisms would 392 allow them to successfully cope with life-threatening infectious disease such as 393 COVID-19. 394

Several age clocks based on different biological parameters have been proposed 395 <sup>38–40,42</sup> and a recent study developed an inflammatory clock (iAge) based on patterns of 396 systemic age-related inflammation tagged to multimorbidity and frailty in the elderly <sup>36</sup>. 397 398 The strongest contributor to iAge was CXCL9, a chemokine involved in cardiac aging and impaired vascular function. Interestingly, CXCL9 is analogous to and from the 399 same family of CXCL10, a mediator highly associated with severity of COVID-19<sup>51</sup> 400 401 (Figures 1 and 2). CXCL9 was found at high levels in hospitalized (Figure 2d), severely diseased (Figure 2e, f) patients and in the elderly from Belo Horizonte and 402 403 Governador Valadares regardless of their infection status (Figure 2d). Therefore, at early stage of infection, severe COVID-19 could be distinguished from other clinical 404 405 forms of the disease by a strong biomarker of aging.

Alongside with the inflammaging phenomena, immunosenscence is marked by several changes in innate and acquired immunity being lymphocytes and the T cell compartment the most affect ones. During aging, thymic atrophy, sustained replicative pressure due to homeostatic proliferation and clonal expansion after antigenic stimulation leads to the emergence of terminally differentiated T cells such as exhausted

and senescent cells. Although these T cell populations share common features such as 411 functional remodelling and cell cycle arrest, they have also distinctive characteristics <sup>52</sup>. 412 Chronically stimulated T cells during aging, persistent viral infections and cancer 413 414 trigger an exhausted profile characterized by the expression of inhibitory receptors such as programmed cell death protein 1 (PD-1) 53,54, inducible costimulatory molecule 415 (ICOS) <sup>53,54</sup> and T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory 416 motif domain (TIGIT) 55. Exhausted T cells display a dysfunctional and non-417 proliferative state that is reversible. On the other hand, immune and non-immune 418 419 senescent cells present a non-reversible loss of their proliferative capacity and acquire a senescence associated secretory phenotype (SASP) that contributes to inflammaging  $5^{6}$ . 420 Expression of CD57<sup>56</sup> and killer cell lectin-like receptor G subfamily member 1 421 (KLRG1)<sup>56</sup> as well as the loss of the co-stimulatory molecule CD28<sup>56</sup> are considered 422 423 indicators of terminal differentiation and are associated with the senescence profile of T lymphocytes. Although KLRG1 also emerges on the cell surface after differentiation, 424 the signalling generated by this molecule regulates a pathway related to exhaustion, 425 making it a marker of both cellular senescence and exhaustion <sup>56</sup>. 426

Notably, we also detected, in patients with severe COVID-19, an accrual of 427 CD8<sup>+</sup> T cells expressing markers of senescence (TIGIT) and exhaustion (ICOS) (Figure 428 429 **3a, b)** as well as increase in frequencies of senescent CD4<sup>+</sup>TIGIT<sup>+</sup> T cells. Using CD28, KLRG1, CD57, TIGIT, PD-1 and ICOS as biomarkers, higher frequencies of CD8<sup>+</sup> and 430 431  $CD4^+$  T cells with mixed senescence/ exhaustion phenotypes were also observed individuals with severe COVID-19 when compared to individuals with mild disease 432 433 and, for specific phenotypes, to individuals with moderate disease (Figure 3). This 434 association of T cell senescence to COVID-19 severity further confirmed our hypothesis and prompt us to examine other parameters of aging as risk factors for the worse disease 435 436 outcomes.

To further understand the influence of B cell senescence in SARS-CoV-2 infection, we explored the immunoglobulin repertoire of COVID-19 patients and healthy individuals. Aging is associated with decreased lymphoid differentiation and with a consequent reduction in the output of naïve B cells. Clonal expansion of memory-like B cells in the periphery due to homeostatic proliferation and chronic stimulation by antigens result in maturation and shrinkage of the immunoglobulin repertoire <sup>7,8</sup>. Herein, we analyzed the most expanded clones to have a better grasp of

15

their representation in the overall repertoire. As shown in **Figure 4a**, the most expanded 444 445 clones were not as dominating in individuals who tested negative for the disease when compared to the one who had a mild outcome. Also, we observed that individuals who 446 447 were hospitalized had the most expanded clones representing a larger amount of the repertoire. In addition, hospitalized patients had lower repertoire diversity when 448 compared to both negative and mild COVID-19 individuals (Figure 4b). These results 449 450 correlated with previous reports demonstrating that the more severe the COVID-19 the lower the diversity of the antibody repertoire <sup>57,58</sup>. In addition, the immunoglobulin 451 repertoire of individuals who needed to be hospitalized had a more mature profile 452 (Figure 4c) characterized by altered immunoglobulin gene usage and an increased 453 454 frequency of mutated antibodies structurally diverging from their germline precursors. Mature repertoires are indicators of immunosenescence because mutations accumulated 455 456 with age as the frequency of germline-encoded antibodies decrease<sup>8</sup>.

To further explore the idea that individuals who developed severe COVID-19 might have an immunosenescent phenotype, we sought to investigate the biological age of individuals within our cohort measuring DNA methylation in CpG dinucleotides. Many studies have used DNA methylation as an epigenetic clock to measure biological age since DNA methylation accumulates with aging <sup>38</sup>. The epigenetic age can be accelerated by certain diseases including HIV infection, Alzheimer's, obesity, and by chronic exposure to infectious agents even when the individuals are not infected<sup>42,16</sup>.

464 To increase the accuracy in measuring biological age by an epigenetic approach, we analyzed the DNA methylation data using 8 different clocks: the classic and updated 465 Horvarth clocks <sup>59</sup>, Hannum's, Levine's, the BLUP, Wu, EN and TL clocks, the latter 466 focused CpGs associated with telomere formation, expression. 467 on and maintenance<sup>27,43,46</sup>. Our results show an acceleration of epigenetic age in hospitalized 468 patients with severe COVID-19 in 7 of the 8 analyzed clocks if we exclude individuals 469 from Governador Valadares. Including this population, we found a similar profile result 470 471 (Figure 4d) with a variation in one of the clocks. However, there is an increase in 472 statistical significance in the analysis when individuals from the endemic area were 473 included (Figure 4e). Thus, these data confirmed, by another approach, the tight association between the immunosenescence phenotype and COVID-19 severity. 474 Moreover, a network analysis of integrated data on the immunosenescence profile 475 showed that individuals who developed severe COVID-19 had clusters with higher 476

degree of integration mostly among senescent and exhausted of T cells (Figure 4 f). A
graphical representation of all data illustrates that individuals with severe disease
resemble the aged phenotype (Figure 4 g).

480 There were limitations in this study. Although we included only individuals with 481 initial infection (1-4 days of symptoms), we cannot exclude the overlap between the inflammatory mediators coming from a previous state of inflammaging from the early 482 483 innate response to SARS-CoV-2. This was less relevant for the analysis of senescent 484 and exhausted T cells because we have shown that COVID-19 can induce senescence and exhaustion in  $CD8^+$  and  $CD4^+$  T cells after 7 days of symptoms <sup>27</sup>. It is probably the 485 case of the repertoire analysis of antibodies that are very unlikely to have expanded due 486 to virus stimulation in such short time of infection. However, the choice of working 487 488 with individuals within 1-4 days of symptoms and the need to match all the individuals 489 by sex, age and presence of comorbidities reduced our study sample, which was another 490 limitation.

491 Despite these restrictions, our data clearly show a close association between a 492 profile of immunosenescence, examined by different approaches and consolidated by network analysis, and the progression of early phase infected individuals to severe 493 494 COVID-19. We also reached important non-anticipated conclusions such as the 495 uniqueness of the inflammatory pattern associated with early COVID-19 when compared to other respiratory infections and the differences in the inflammaging and 496 497 immunesenescence phenotype in endemic regions for infectious disease when compared 498 other metropolitan areas. These results are relevant not only to uncover the pathogenesis 499 of severe COVID-19, but they have also predictive value for future epidemic viral 500 infections. Most of all, the data shed light on the aging process and on the consequences 501 of accelerated senescence that affect certain endemic regions of the planet.

502

#### 503 Author contribution:

A.M.C. designed the study, coordinate the recruitment and analysis, and wrote the manuscript; L.H.A.V. and L.T. performed sample collection and processing, Luminex and flow cytometry analysis, and wrote the manuscript; G.C.C. performed the recruitment, blood collection and sample processing of the volunteers in Belo Horizonte, discussed the results and wrote the manuscript; J.Z. performed flow

cytometry analysis of samples from São Paulo and discussed the results, M.M.C. 509 510 performed DNA methylation analysis and discussed the results; C.H.R-P. was in the charge of sample processing and helped with the flow cytometry analysis, J.G. 511 512 performed the B cell repertoire analysis and discussion under the supervision of L.F.F., F.C.M. performed the bioinformatic analysis and discussed the results; L.N. developed 513 the database for the study, M.A.O., V.D.M. and M.F.O. helped in sample processing, 514 515 Luminex analysis and discussion of the results, L.W.Z. helped with B cell repertoire and 516 DNA methylation analysis and the discussion of the results; M.S.C. performed the 517 clinical exams of volunteers at UPA-Centro Sul in Belo Horizonte under the supervision of U.T.; H.I.S. performed the RT-PCR tests of all volunteers under the supervision of 518 519 S.M.R.T.; H.C.G. and R.C.B. were in charge of clinical exams of volunteers recruited at Hospital Universitário Risoleta Tolentino Neves in Belo Horizonte; A.P.V., N.A., 520 521 G.P.C. and S.R. were in charge of clinical exams of volunteers recruited at Instituto de Infectologia Emílio Ribas, M.L.O.J. was in the charge of the clinical exams of 522 523 volunteers recruited at Hospital Unimed in Governador Valadares; A.P.C.B. helped in 524 the recruitment and sample processing of volunteers in Governador Valadares; F.F.C. helped in recruitment, sample collection and processing in Belo Horizonte; E.S.F. 525 526 helped with the Luminex testing and data analysis supervised by O.A.M.F.; V.C. helped in the bioinformatic and statistical analysis as well as the discussion of the results, R.A. 527 was in the charge of radiographic classification and follow-up of hospitalized patients in 528 São Paulo; R.S. helped in the recruitment of healthy volunteers in São Paulo; G.S-N. 529 coordinate all the recruitment and sample collection/processing of volunteers from 530 531 Governador Valadares and helped in the statistical analysis; M.A. and C.L. helped in 532 sample processing and the flow cytometry analysis of volunteers from São Paulo, T.U.M. coordinate the recruitment, questionnaire application and telemonitoring of 533 volunteers of Belo Horizonte and helped discussing the data; D.M.F. coordinate sample 534 processing and flow cytometry analysis in São Paulo, helped designing the experiments 535 536 and discussing the data; A.T-C. supervised the flow cytometry analysis, Luminex 537 analysis, serology tests in Belo Horizonte, helped designing the experiments and discussing the data. 538

539

# 540 Acknowledgments:

This study was supported by grants from Merck Dohme & Sharp (MISP#60383), 541 542 Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil, 407363/2021-1), Coordenação de Aperfeiçoamento de Pessoal do Ensino Superior 543 544 (# 0688/2020, CAPES, Brazil) and Pro-reitoria de Pesquisa da Universidade Federal de Minas Gerais (PRPq-UFMG). A.M.C.F., A.T-C., D.M.F., T.U.C., O.A.M.F., G.C.C., 545 M.M.C., M.A.O., M.F.O., V.D.M. are recipients of research fellowships and 546 547 scholarships from CNPq, L.H.A.V., L.T., L.N. are recipients of scholarships and 548 fellowships from CAPES, Brazil, F.C.M. is recipient of a scholarship from Fundação de 549 Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG, Brazil), M.A. and C.L. are recipients of a scholarships from Fundação de Amparo à Pesquisa do Estado de São 550 551 Paulo (FAPESP, Brazil).

552

# 553 Conflict of Interest Statement

- 554 The authors do not have any conflicts of interest regarding this manuscript, its
- 555 preparation, or the research that went into it.
- 556

#### 557 Data availability statement

- 558 The MiAIRR data that support the findings of this study are available in Zenodo with
- the identifier(s) doi:10.5281/zenodo.12789370. FASTQ files can be accessed via NCBI
- under the BioProject accession PRJNA1138747 or SRA SRP528303, in the project
- 561 Immunosenescence of antibody repertoire in individuals from endemic areas for
- 562 infectious diseases or via the link:
- 563 <u>https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1138747</u>.
- 564 Data are also available upon request to the corresponding author.
- 565

# 566 Materials and Methods

567 *Ethics Statement* 

The present study was approved by the national research ethics committee in Brazil (CONEP) and by the research ethics committees of the Universidade Federal de Minas Gerais (UFMG), and of the Instituto de Infectologia Emílio Ribas (IIER) (CAAE 40208320.3.2001.0061). All participants signed the informed consent form during the first evaluation, agreeing to participate in the study.

573

#### 574 Study Population and Data Collection

575 A total study sample of 806 volunteers were recruited in 3 cities, Belo Horizonte/MG (467 individuals), Governador Valadares/MG (176 individuals) and São 576 577 Paulo/SP (163 individuals) from December 2020 to October 2021 (Table 1 and 2). The 578 strains that circulated during the period were the original and P1 (Brazilian variant). Individuals with symptoms of a flu-like syndrome of unknown ethiology and healthy 579 580 individuals were used as study controls. Volunteer recruitment in Belo Horizonte (MG) was carried out at the Health Care Unit in the Center-South region (UPA-CS), at 581 Hospital Risoleta Tolentino Neves, at Casa do Ancião in Cidade Ozanam and at home. 582 In São Paulo (SP), volunteer recruitment and sample collection took place at the 583 Instituto de Infectologia Emílio Ribas (IIER) and in Governador Valadares (MG), at 584 585 Hospital da Unimed de Governador Valadares and at home for some exceptional cases. A study flowchart with an outline of recruitment and sample collection at the health 586 units is shown in Supplementary Figure 4. All individuals had their blood collected 587 588 and were tested using nasopharyngeal swabs samples for reverse-transcriptase quantitative polymerase-chain-reaction (RT-qPCR) detection of SARS-CoV-2. They 589 590 were telemonitored for 14 days to obtain information on their clinical status. 591 Hospitalized individuals had their clinical evolution information collected directly from their medical records. All volunteers had their weight and height measured to determine 592 their nutritional status by using the Body Mass Index (BMI) ratio. Weight was assessed 593 using a Balmark<sup>®</sup> device with a capacity of 200 kg and an accuracy of 100 g, while 594 height was measured with a portable stadiometer that accommodates up to 2 meters 595 with an accuracy of 1.0 mm. The Body Mass Index (BMI) was calculated using the 596 597 formula: BMI = weight (kg) / height<sup>2</sup> (m) and was subsequently classified according to their age range, based on the World Health Organization scale <sup>60</sup>. A clinical and 598 sociodemographic questionnaire was also administered during recruitment to gather 599 600 additional information, such as current symptoms, days since symptom onset, 601 vaccination status, and medical history.

602

## 603 Study inclusion and exclusion criteria

20

Initially, the inclusion criteria for the study groups were all individuals over 20 years of age who had flu-like symptoms at the time of data collection. For negative individuals, the inclusion criterion at recruitment was all individuals who were never diagnosed with COVID-19 nor had flu-like symptoms with a confirmed negative RT-PCR test for SARS-CoV-2 infection and who tested negative for serological quantification of the following 4 viral proteins: spike 1, spike 2, nucleocapsid and receptor binding domain (RBD).

611 Exclusion criteria were applied to any patient who took any dose of the COVID-19 vaccine, patients living with HIV, those with inconclusive RT-PCR test, missing 612 613 important information in their medical records or in the health questionnaire, those with greater than 4 days of symptom onset and those with a positive anti-SARS-CoV-2 IgG 614 or IgM serology. We included only individuals who had 1 to 4 days of symptoms to 615 616 better assess possible predictors of the disease. As shown previously by our group, individuals with mild and severe COVID-19 presented an increase in the frequency of 617 exhausted/senescent T cells and in the levels of inflammatory mediators after 7 days of 618 619 symptoms with a clear difference between the ones with only 4 days of symptom onset<sup>27</sup>. 620

621

# 622 Clinical Groups and Criteria for Classification of COVID-19 Patients

We classified those infected with COVID-19 (positive RT-PCR for SARS-CoV-623 2) into different clinical forms of COVID-19 (mild, moderate and severe) according to 624 WHO criteria (Supplementary Table 1). To perform certain analysis, we chose to 625 group individuals with a moderate or severe clinical form of COVID-19 in a single 626 627 group called Hospitalized since these individuals needed inpatient care. Individuals with 628 flu-like symptoms who presented a negative RT-PCR and serological test for SARS-CoV-2 were grouped in the flu-like syndrome (FLS) group. A group of negative 629 individuals was used in some analysis, and it consists of individuals with a negative 630 631 SARS-CoV-2 test and no report of flu-like symptoms.

632

#### 633 **RT-PCR** for SARS-CoV-2 detection and viral load calculation

21

RNA extraction from nasopharyngeal swab samples was performed using the 634 QIAamp Viral RNA Mini Kit (Qiagen, Germany) according to the manufacturer's 635 protocol. From 1 mL of Viral Transport Medium containing the collected sample, 47 µL 636 637 of each individual sample was pooled in 1.5 mL microtubes, and 150 µL of the pool was used for extraction; the remainder was stored at -80 °C for possible repetitions. In 638 cases where the clustering resulted in detectable results, it was necessary to individually 639 640 process all samples present in the respective cluster. RT-qPCR was performed using the 641 QuantStudio<sup>TM</sup> 3 and 5 real-time PCR systems (Applied Biosystems<sup>TM</sup>, United States). For viral RNA detection, the recommendations described by the Charité protocol<sup>61</sup> 642 were followed, which targets the gene (E) encoding the viral envelope protein, with a 643 reported sensitivity of 3.9 copies of the SARS-CoV-2 genome per reaction <sup>61</sup>. Thermal 644 cycling was performed at 55°C for 10 min for reverse transcription, followed by 95°C 645 646 for 3 min and then 45 cycles of 95°C for 15 s, 58°C for 30 s. For endogenous control of the reaction, the gene encoding human RNaseP was used as a target. 647

648

#### 649 Blood collection and isolation of PBMC

Peripheral blood mononuclear cells (PBMC) were obtained by blood collection 650 from COVID-19 and control patients using heparinized vacuette. The purification was 651 652 attained by Ficoll gradient (Histopaque - 1077; Sigma) centrifugation at room temperature, in a 1:2 ratio, for 40 minutes, at 1400 resolutions per minute (RPM) 653 654 without breaking. After that, PBMCs were collected using a Pasteur pipette, washed 655 with RPMI medium at 500x for 7 minutes at 4°C, and then red cells were lysed using a lysis buffer. A second wash using RPMI was conducted. Cells were counted and stored 656 in fetal bovine serum supplemented with 10% dimethyl sulfoxide at -80°C until use. 657 Samples were processed up to 48 hours after collection. 658

659

#### 660 Plasma and Serum Isolation

Blood was collected into heparin tubes for plasma obtention, and in serum separator tubes containing clot activator. Plasma and serum samples were isolated after whole blood centrifugation at 3000 RPMs for 10 minutes at 20°C, then carefully split into 2mL aliquots and stored at -80°C until the time of testing, Samples were processed up to 48 hours after collection.

666

#### 667 Measurement of cytokines, chemokines, and growth factors by Luminex-Multiplex

668 The measurement of biomarkers was performed in heparinized plasma for 669 detection and quantification of analytes for all 309 individuals from Belo Horizonte, 670 São Paulo and Governador Valadares (endemic area) all in Brazil. The Bio-Rad 671 Laboratories kit (Bio-Plex® Pro Human Cytokine Standard) was used, allowing for the analysis of several analytes to be analyzed simultaneously, using the magnetic 672 673 immunoassay technique carried out with the Luminex equipment (Bio-Plex® 200, Bio-Rad), following storage and processing protocols standardized by the Grupo Integrado 674 de Pesquisa com Biomarcadores (GIPB) (IRR-FIOCRUZ/MG). Samples were 675 transported and stored at a temperature of -80°C. Analyses were performed using 676 Bioplex<sup>TM</sup> xPONENT version 3.1 software (Bio-Rad), and presented the following 677 678 panel of analytes: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, CXCL8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, CCL11, Basic-FGF, G-CSF, GM-CSF, IFN-γ, CXCL10, 679 680 CCL2, CCL3, CCL4, PDGF-BB, CCL5, TNF and VEGF.

In all the inflammatory analysis carried out in the present study, we identified 10 of the 27 mediators evaluated as those that are most present in the analyses, configuring a possible signature of these mediators in our population (CCL2, CXCL8, CXCL10, IL-6, IL12(p70), IFN- $\gamma$ , IL-1Ra, IL-10, TNF, IL-6) and in order not to dilute the data, we chose to show the differences only within this signature.

686

#### 687 Measurement of chemokines by Cytometric Bead Array (CBA)

The CBA assay was performed using the BD Cytometric Bead Array (CBA) – Human Chemokine Kit to complete the Luminex Bio-plex assay biomarker panel. The chemokines present in the kit are CCL2, CCL5, CXCL8, CXCL9 and CXCL10. Samples from Belo Horizonte-MG, Governador Valadares-MG and São Paulo-SP, all previously prepared before the test, were included. Kit reagents were previously filtered, and kit protocol was standardized and used. Samples were purchased from BD FACSVerse.

695

#### 696 Measurement of SARS-CoV-2 viral proteins by Luminex-Multiplex

23

The measurement of biomarkers was performed in serum for detection and 697 quantification of proteins for 144 negatives individuals from Belo Horizonte, São Paulo 698 and Governador Valadares (endemic area) all in Brazil. The Bio-Plex Multiplex SARS-699 700 CoV-2 Serology Assay Kit was used, allowing the analysis of the following viral 701 proteins: Spike 1, Spike 2, Nucleocapsid and receptor binding domain (RBD). All 702 samples were analyzed simultaneously using the magnetic immunoassay technique 703 performed with the Luminex equipment (Bio-Plex® 200; Bio-Rad) and according to the 704 storage and processing protocols standardized by the Grupo Integrado de Pesquisa com Biomarcadores (GIPB) (IRR - FIOCRUZ/MG). Samples were transported and stored at 705 706 -80°C. Analysis were performed using Bioplex<sup>™</sup> xPONENT software version 3.1 (Bio-707 Rad).

708

#### 709 Measurement of Vitamin D

The biochemical test to measure vitamin D levels was outsourced to a clinical analysis laboratory in Belo Horizonte, which has all the laboratory quality certifications in order. The serum levels of this vitamin were measured by chemiluminescence using the Atellica Siemens device. All tests were performed respecting the transport and storage conditions established by the outsourced company.

715

# 716 Immunophenotype by polychromatic flow cytometry

PBMCs  $(1 \times 10^6)$  were first stained with LIVE/DEAD fixable aqua dead cell stain 717 (ThermoFisher Scientifc, cat #L34957) and with fluorophore-conjugated monoclonal 718 719 antibodies to human surface markers. All information on the antibodies, their 720 concentrations, manufacturer and catalogue numbers can be found in **Supplemmentary** Table 2. After the surface staining, cells were fixed and permeabilized using the 721 722 Foxp3/Transcription Factor Staining Buffer Set from eBioscience (cat #00-5523-00) and stained for -Foxp3 from ImmunoTools (3G3, cat# 21276106) (Supplemmentary 723 Table 2). Single-color labelled cells for fluorescence compensation were prepared with 724 725 antibody capture compensation beads (BD Biosciences). Cell samples were acquired in 726 a BD LSRFortessa cell analyzer (BD Biosciences) coupled to computers with DIVA and FlowJo-10 software (Tree Star). One hundred events for each sample were acquired 727

24

in the lymphocyte gate. The gate strategy used to analyze T lymphocyte populations is

shown in **Supplementary Figure 3**.

730

# 731 Extraction of DNA and RNA from PBMC and Bisulphite Treatment

Frozen samples of PBMCs were briefly thawed in a 37°C water bath and kept on 732 733 ice. Pellets were then resuspended in 1ml Trizol and incubated at room temperature. 734 Chloroform was then added to each sample. After homogenization and further 735 incubation, samples were centrifuged to form a three-phase solution. The aqueous phase 736 was used for RNA extraction and the interphase was used for DNA extraction. Thus, 737 both samples underwent purification and quantification steps and, after elution, were 738 stored in a -80°C freezer in low-binding plastic microtubes. Genomic DNA extraction was performed using the QIAamp 96 DNA Blood kit (QIAGEN, Hilden, Germany). 739 740 DNA (1 µg) was bisulphite-converted using the EZ-96 DNA Methylation Kit (Zymo Research, Irvine, USA) with the following modifications: incubation in CT buffer for 741 21 cycles of 15 min at 55 °C and 30 s at 95 °C, elution of bisulphite-treated DNA in 100 742 µl of water. After extraction and conversion, samples were loaded on the Illumina 743 Infinium MethylationEPIC BeadChip. 744

745

# 746 Analyses of Epigenetic Aging: Obtaining Raw Methylation Data

DNA from the PBMC samples was extracted according to the Trizol and chloroform protocol. Subsequently, DNA was hybridized using the Illumina Infinium MethylationEPIC Beadchip (EPIC array) that covers nearly 850,000 CpG sites in the human genome. The watermelon 2.4.0 R package (Pidsley et al., 2013) was used to perform raw data processing, batch effect correction, and obtain matrices with methylation  $\beta$  value. The methylation  $\beta$  value for each CpG site in each sample was calculated to represent the level of methylation.

754

## 755 DNA methylation age calculation

We used the mDNA age of epigenetic clocks created based on blood samples, including the Horvath clock with 353 CpGs based on various tissue types, the

25

skinHorvath clock that integrated the whole blood dataset with skin, endothelial cells, 758 buccal mucosa and saliva, the Levine clock based on 513 CpGs derived from whole 759 blood, the TL telomere length clock based on 140 CpGs derived from blood, the BLUP 760 761 clock based on 319607 CpGs derived from blood, the EN clock based on 514 CpGs derived from all blood and the Hannum watch with 71 CpGs identified in blood DNA 762 samples. The deviation between epigenetic age and chronological age, also known as 763 764 epigenetic age acceleration, was calculated for each sample based on mDNA age 765 regression residuals considering cell counts with the R methylclock 1.5.0 package <sup>62</sup>.

766

# 767 *B* cells repertoire analysis using immunoglobulin variable heavy chain (IGVH) 768 amplification

A subset of 45 individuals was analyzed to examine their B cell repertoire. For this, 769 770 RNA was extracted from frozen PBMC samples of these individuals using Trizol (ThermoFisher). The cDNA was synthesized with SuperScript IV First-Strand Synthesis 771 System (ThermoFisher) from approximately 500 ng of RNA, following the 772 manufacturer's instructions. IGVH amplification was performed using 0.2 mM of 773 forward primers (1 to 8; Supplementary Table 4), 0.1 mM of each IgG and IgA 774 775 reverse primers (9 and 10; Supplementary Table 4), 0.2 units (U) of Platinum<sup>™</sup> Tag 776 DNA Polymerase High Fidelity (Invitrogen), 1X High Fidelity PCR Buffer solution, 0.2 mM of dNTPs, 1 mM of MgSO<sub>4</sub>, and 2  $\mu$ L of cDNA in a final volume of 50  $\mu$ L. The 777 778 PCR reaction was conducted using the following program: 2 minutes (min) at 95 °C; 4 779 cycles of 94°C for 30 seconds (sec), 50°C for 30 sec, and 68°C for 1 min; 4 cycles of 94°C for 30 sec, 55°C for 30 sec, and 68°C for 1 min; 22 cycles of 94°C for 30 sec, 780 781 63°C for 30 sec; 68°C for 7 min and final hold at 4°C. Samples GV47, GV50, GV51, 782 GV54, GV92, GV106, GV144, and GV146 were amplified using the NEBNext® High-Fidelity 2X PCR Master Mix (New England Biosciences, UK). Forward primers at a 783 final concentration of 0.2 mM, IgG/IgA reverse primers at 0.1 mM, and 2 µL of cDNA 784 were added to 1x PCR Master Mix in a final volume of 50 µL. The cycling conditions 785 were the same as described above, except for an extension temperature of 72° C. Four 786 replicates were amplified for each sample. The mixed 200 µL of PCR product of each 787 sample was precipitated using Puregene® Concentrating DNA protocol (Qiagen, 788 Germany). IgG/IgA amplification was excised from an electrophoresis run of 1% 789 790 agarose gel, followed by the PCR purification protocol provided by NucleoSpin Gel and

26

791 PCR Clean up kit (Macherey-Nagel). The concentration of the DNA was calculated

vising Nanodrop and Qubit DNA High Sensitivity kit (ThermoFisher Scientific).

793

# 794 Library construction and sequencing

Sequencing libraries were constructed using the Nextera XT DNA Library Prep Kit 795 (Illumina) according to the manufacturer's instructions. A PCR reaction was prepared to 796 797 contain: 5 µl of Nextera CD Index 1 (i7) Primer (H7XX); 5 µl of Nextera CD Index 2 798 (i5) Primer (H5XX); 1X of the High-Fidelity PCR Buffer solution; 0.2 mM of dNTPs; 1 799 mM of MgSO<sub>4</sub>; 1 U of Platinum® Taq DNA High Fidelity Polymerase; 5 µl (if DNA concentration >= 10 ng/µl) or 10 µl (if DNA concentration ranged from 5 -10 ng/µl) of 800 801 the gel purified amplicon in a final volume of 50  $\mu$ l. The cycling condition was 3 min at 95 °C; 12 cycles of 94°C for 30 sec, 55°C for 30 sec, and 68°C for 1 min; 68°C for 5 802 min; and hold at 4°C. The PCR product was purified with 0.5 volumes of Agencourt 803 804 AMPure XP beads and the library was quantified using the Oubit DNA High Sensitivity kit (ThermoFisher Scientific). Amplicon size was inferred using the High Sensitivity 805 DNA Kit (Agilent) run on the Bioanalyzer 2100 (Agilent). Sequencing was performed 806 on the Illumina MiSeq System (Illumina), using the Miseq Reagent Kit v3 (600-Cycle) 807 808 (Illumina) with 301 sequencing cycles for each forward and reverse read. A total of 31 809 different libraries from the volunteers were joined equimolarly in a pool of 4nM and diluted to 18 picomolar for further sequencing. A summary of found sequences are in 810 **Supplementary Table 4.** 811

812

# 813 Bioinformatic analysis: Pre-processing

814 Samples were demultiplexed by the Illumina sequencer tool or using an in-house script resulting in FASTO files. All pre-processing was done using the framework 815 Immcantation and it consists of 4 steps: 1) Using pRESTO <sup>63</sup>, the AssemblePairs 816 module was used to join the sequence, based on the 3'-5' read and the 5'-3' read, with a 817 minimum overlap of 50 nucleotides; 2) Quality filter was applied by using the module 818 FilterSeq  $^{63}$  Only sequences with a Phred score >=30 were selected; 3) The module 819 MaskPrimers<sup>63</sup> was employed to find the primers of the IGHV gene and constant 820 821 region. The option score was employed, preserving sequences with both forward and

27

reverse primers intact; any sequences not meeting these conditions were filtered out; 4) 822 Annotation was performed with the AssignGenes module from Change-O<sup>63</sup> together 823 with IgBlast<sup>64</sup> to verify similarities between the subject and query. IMGT human 824 germline was used as a reference for V, J, and D genes, as well as their numbering 825 system <sup>65</sup>; the MakeDB module was run to organize the alignment into a tabular .tsv file 826 in the MiAIRR format <sup>66</sup>. This format contains information on V, D, and J genes and 827 alleles, framework (fw), complementary regions sequences (cdr), and functional status 828 829 of the sequence (productive or unproductive).

830

#### 831 Bioinformatic analysis: Clonotyping and Diversity Analysis

The sequences were grouped into clones using the tool YClon<sup>67</sup>. Shannon diversity was 832 calculated using the diversity function of the R package 'vegan' (https://CRAN,R-833 834 project,org/package=vegan). Diversity was compared between groups of individuals with flu-like symptoms or control (n=6), with the ones with mild COVID (n=19), and 835 severe COVID-19 (n=20) from Belo Horizonte, São Paulo and Governador Valadares 836 837 (only mild cases). Diversity was computed for the 100 most expanded clones from each repertoire. The complete pipeline employed to prepare and analyze the IGH repertoire is 838 839 available on https://github.com/jao321/covidao.git.

840

#### 841 *Repertoire Maturity Analysis*

842 We define repertoire maturity as the extent to which an individual's immune repertoire has diverged from germline-like sequences through processes such as somatic 843 844 hypermutation and clonal selection. A more mature repertoire is characterized by a 845 lower proportion of germline-like clones, reflecting immune system adaptation and experience with antigens over time. To gain a more profound insight into the maturity 846 of the repertoire, an investigation was conducted to identify the sequence closest to the 847 germline for each clone, encompassing both the V and J genes. To achieve this, we 848 849 considered the difference in length between the V gene (5 to 6 times longer than the J gene) to ensure a comprehensive analysis, using the following calculation: 850

851 VJpid =(Vpid \*0.8)+(Jpid \*0.2)

28

VJpid: Percentage of the expected identity of the V and J genes when compared to
the germline

854 VJpid: Percentage of identity of V genes compared to germline

855 VJpid: Percentage of the identity of the J gene when compared to the germline

856 Only the sequence with the highest VJpid value for each clone remained, as these

sequences have undergone fewer mutations.

858

## 859 Statistical Analysis

860 The Shapiro-Wilk and Kolmogorov-Smirnov tests were applied to determine whether 861 the data had a normal (parametric) or non-normal (non-parametric) distribution. Outliers 862 were excluded using the ROUT test. For each group, Mann-Whitney test or Kruskal-863 Wallis with Dunn's post-test was performed depending on the data distribution normal 864 or non-normal. The violin plot was chosen to demonstrate the statistical significance of 865 our analyses. Its format is directly proportional to the dispersion of the data, the dotted lines correspond to the minimum quartiles in the lower part and maximum in the upper 866 part, and the solid line represents the median. Data are represented by black dots (each 867 868 dot represents an individual) and were normalized in log10. In addition, all groups 869 received a specific color that represents them in all graphs and figures.

870

## 871 Radar-Chart

The radar chart is a graph that represents the frequency (in percentage) of high 872 producers of each plasma mediator represented and it has been previously described  $1^{1/2}$ . 873 874 On the charts, each axis represents the percentage (%) of volunteers showing high levels 875 of a specific mediator. The values of each axis can be connected to form a central 876 polygonal area that represents 50% of the baseline level and the external polygonal area is equivalent to 100%. Increase or decrease of the central polygonal area reflects either 877 a higher or a lower contribution of the mediators for each group. We consider all 878 879 mediators that are above the internal polygonal area to be high producers.

880

#### 881 Network analysis

A weighted network analysis was used to investigate the correlations between
biologically relevant markers associated with cytokines and cellular proteins (listed in

**Supplementary Table 5** and selected based on their potential relevance for the study). 884 885 To quantify the relationships between these markers, we utilized Spearman Rank correlation, a non-parametric method that ranks the data points for each variable and 886 887 calculates the correlation coefficient based on the ranks. This approach is suitable for data that may not follow a normal distribution or have outliers. The correlation 888 889 coefficient ranges from -1 to 1, where 1 indicates a perfect positive correlation, -1 890 indicates a perfect negative correlation, and 0 indicates no correlation. To focus on 891 significant correlations, we established a threshold of p-values less than 0.05. This 892 filtering step ensured that only statistically significant relationships were included in the 893 network analysis. The resulting network was visualized using a spring layout, a graph 894 drawing algorithm that positions nodes based on the forces of attraction and repulsion between them. This layout is particularly effective for identifying clusters or modules 895 896 within the network, providing insights into the underlying structure of the relationships. 897 The strength of correlations was visually represented by the darker of the lines 898 connecting nodes. Darker lines indicated stronger relationships between variables, while 899 lighter lines suggested weaker associations. Additionally, the size of each node 900 corresponded to the number of correlations it participated in, providing a visual cue for 901 the variable's centrality within the network. Larger nodes represented variables with 902 more connections, highlighting their importance in the overall system. By visualizing the network in this manner, we were able to gain insights into the interactions between 903 904 cytokines/chemokines and cellular proteins, identifying key players and potential 905 regulatory mechanisms within the biological system under study.

906

## 907 **References**

908	1.	Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons from the
909		Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a
910		Report of 72314 Cases from the Chinese Center for Disease Control and
911		Prevention. JAMA - J. Am. Med. Assoc. 323, 1239–1242 (2020).
912	2.	Grasselli, G. et al. Baseline Characteristics and Outcomes of 1591 Patients
913		Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
914		<i>JAMA</i> <b>323</b> , 1574–1581 (2020).
915	3.	Cerqueira-Silva, T. et al. Influence of age on the effectiveness and duration of

916		protection of Vaxzevria and CoronaVac vaccines: A population-based study.
917		Lancet Reg. Heal Am. 6, 100154 (2022).
918	4.	Cunha, L. L., Perazzio, S. F., Azzi, J., Cravedi, P. & Riella, L. V. Remodeling of
919		the Immune Response With Aging: Immunosenescence and Its Potential Impact
920		on COVID-19 Immune Response. Front. Immunol. 11, (2020).
921	5.	Faria, A. M. C. & Franceschi, C. Population Immunology: Germs, Aging and
922		Inflammation. in <i>Eco-immunology</i> (2014)145-161 (Springer Netherlands, 2014).
923		doi:10.1007/978-94-017-8712-3_8
924	6.	Santoro, A., Bientinesi, E. & Monti, D. Immunosenescence and inflammaging in
925		the aging process: age-related diseases or longevity? Ageing Res. Rev. 71,
926		101422 (2021).
927	7.	Martin, V., Wu, YC. (Bryan), Kipling, D. & Dunn-Walters, D. Ageing of the B-
928		cell repertoire. Philos. Trans. R. Soc. B Biol. Sci. 370, 20140237 (2015).
929	8.	Ghraichy, M. et al. Maturation of the Human Immunoglobulin Heavy Chain
930		Repertoire With Age. Front. Immunol. 11, (2020).
931	9.	Ciabattini, A. et al. Vaccination in the elderly: The challenge of immune changes
932		with aging. Semin. Immunol. 40, 83–94 (2018).
933	10.	Franceschi, C. & Campisi, J. Chronic Inflammation (Inflammaging) and Its
934		Potential Contribution to Age-Associated Diseases. Journals Gerontol. Ser. A
935		<i>Biol. Sci. Med. Sci.</i> <b>69</b> , S4–S9 (2014).
936	11.	Talbot, H. K. Influenza in Older Adults. Infect. Dis. Clin. North Am. 31, 757-766
937		(2017).
938	12.	Kimball, A. et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in
939		Residents of a Long-Term Care Skilled Nursing Facility — King County,
940		Washington, March 2020. MMWR. Morb. Mortal. Wkly. Rep. 69, 377-381
941		(2020).
942	13.	Caruso, C. et al. Lessons from Sicilian centenarians for anti-ageing medicine.
943		The Oxi-inflammatory status. Transl. Med. @ UniSa 24, 16–23 (2022).
944	14.	Torres, K. C. L. et al. Immune senescence and biomarkers profile of Bambuí

945		aged population-based cohort. Exp. Gerontol. 103, 47-56 (2018).
946 947	15.	Lima-Silva, M. L. <i>et al.</i> A nationwide study on immunosenescence biomarkers profile in older adults: ELSI-Brazil. <i>Exp. Gerontol.</i> <b>191</b> , 112433 (2024).
948 949	16.	Durso, D. F. <i>et al.</i> Living in endemic area for infectious diseases accelerates epigenetic age. <i>Mech. Ageing Dev.</i> <b>207</b> , 111713 (2022).
950 951	17.	Silveira-Nunes, G. <i>et al.</i> Lifewide profile of cytokine production by innate and adaptive immune cells from Brazilian individuals. <i>Immun. Ageing</i> <b>14</b> , 2 (2017).
952 953	18.	Batista, M. A. <i>et al.</i> Inflammaging in Endemic Areas for Infectious Diseases. <i>Frontiers in Immunology</i> <b>11</b> , (2020).
954 955 956	19.	Silveira-Nunes, G. <i>et al.</i> Hypertension Is Associated With Intestinal Microbiota Dysbiosis and Inflammation in a Brazilian Population. <i>Front. Pharmacol.</i> <b>11</b> , 258 (2020).
957 958	20.	Comin, F., Speziali, E., Correa-Oliveira, R. & Faria, A. M. C. Aging and immune response in chronic human schistosomiasis. <i>Acta Trop.</i> <b>108</b> , 124–130 (2008).
959 960 961	21.	Sargiacomo, C., Sotgia, F. & Lisanti, M. P. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? <i>Aging (Albany. NY).</i> <b>12</b> , 6511–6517 (2020).
962	22.	Aviv, A. Telomeres and COVID-19. FASEB J. 34, 7247–7252 (2020).
963 964 965	23.	Omarjee, L. <i>et al.</i> Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. <i>Clin. Immunol.</i> <b>216</b> , 108464 (2020).
966 967 968	24.	Bonafè, M. <i>et al.</i> Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. <i>Cytokine Growth Factor Rev.</i> <b>53</b> , 33–37 (2020).
969 970	25.	Cao, X. <i>et al</i> . Accelerated biological aging in COVID-19 patients. <i>Nat. Commun.</i> <b>13</b> , 2135 (2022).
971 972	26.	Franzen, J. <i>et al.</i> Epigenetic Clocks Are Not Accelerated in COVID-19 Patients. <i>Int. J. Mol. Sci.</i> <b>22</b> , 9306 (2021).
973	27.	Pedroso, R. B. et al. RAPID PROGRESSION OF CD8 AND CD4 T CELLS TO

974		CELLULAR EXHAUSTION AND SENESCENCE DURING SARS-CoV2
975		INFECTION. J. Leukoc. Biol. 116, (2024).
976 977 978	28.	Peres, K. C., Riera, R., Martimbianco, A. L. C., Ward, L. S. & Cunha, L. L. Body Mass Index and Prognosis of COVID-19 Infection. A Systematic Review. <i>Front.</i> <i>Endocrinol. (Lausanne).</i> <b>11</b> , 5985–6004 (2020).
979 980 981	29.	Wang, B., Li, R., Lu, Z. & Huang, Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. <i>Aging (Albany. NY).</i> <b>12</b> , 6049–6057 (2020).
982 983	30.	Hayden, F. G. <i>et al.</i> Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. <i>N. Engl. J. Med.</i> <b>379</b> , 913–923 (2018).
984 985	31.	Sun, J. <i>et al.</i> Pathogenicity of fowl adenovirus serotype 4 (FAdV-4) in chickens. <i>Infect. Genet. Evol.</i> <b>75</b> , 104017 (2019).
986 987 988	32.	Juanola-Falgarona, M. <i>et al.</i> Ct values as a diagnostic tool for monitoring SARS-CoV-2 viral load using the QIAstat-Dx® Respiratory SARS-CoV-2 Panel. <i>Int. J. Infect. Dis.</i> <b>122</b> , 930–935 (2022).
989 990 991	33.	Mariani, J. <i>et al.</i> Association Between Vitamin D Deficiency and COVID-19 Incidence, Complications, and Mortality in 46 Countries: An Ecological Study. <i>Heal. Secur.</i> <b>19</b> , 302–308 (2021).
992 993	34.	Marshall, J. C. <i>et al.</i> A minimal common outcome measure set for COVID-19 clinical research. <i>The Lancet Infectious Diseases</i> <b>20</b> , e192–e197 (2020).
994 995	35.	Fulop, T. <i>et al.</i> Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? <i>Front. Immunol.</i> <b>8</b> , (2018).
996 997 998	36.	Sayed, N. <i>et al.</i> Author Correction: An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. <i>Nat. Aging</i> <b>1</b> , 598–615 (2021).
999 1000	37.	Faria, A. M. C. <i>et al.</i> Variation Rhythms of Lymphocyte Subsets during Healthy Aging. <i>Neuroimmunomodulation</i> <b>15</b> , 365–379 (2008).
1001 1002	38.	Horvath, S. DNA methylation age of human tissues and cell types. <i>Genome Biol.</i> <b>14</b> , R115 (2013).

1003	39.	Levine, M. E. et al. An epigenetic biomarker of aging for lifespan and
1004		healthspan. Aging (Albany NY) 10, 573–591 (2018).
1005	40.	Hannum, G. et al. Genome-wide Methylation Profiles Reveal Quantitative Views
1006		of Human Aging Rates. Mol. Cell 49, 359-367 (2013).
1007	41.	Lu, A. T. et al. DNA methylation-based estimator of telomere length. Aging
1008		(Albany. NY). <b>11</b> , 5895–5923 (2019).
1009	42.	Field, A. E. <i>et al.</i> DNA Methylation Clocks in Aging: Categories, Causes, and
1010		Consequences. <i>Mol. Cell</i> <b>71</b> , 882–895 (2018).
1011	43	Tizazu A M Mengist H M & Demeke G Aging inflammaging and
1011	13.	immunosenescence as risk factors of severe COVID-19. <i>Immun. Ageing</i> <b>19</b> , 53
1013		(2022).
1014	44.	Camell, C. D. et al. Senolytics reduce coronavirus-related mortality in old mice.
1015		Science (80 ). <b>373</b> , (2021).
1016	45	Arcanio A <i>et al</i> Critically ill COVID-19 patients exhibit hyperactive cytokine
1010	чэ.	responses associated with effector exhausted senescent T cells in acute infection
1017	1.5	
1018	46.	Biasi, S. De <i>et al.</i> Marked T cell activation, senescence, exhaustion and skewing
1019		(2020)
1020		(2020).
1021	47.	Lucas, C. <i>et al.</i> Longitudinal analyses reveal immunological misfiring in severe
1022		COVID-19. <i>Nature</i> <b>584</b> , 463–469 (2020).
1023	48.	Santoro, A. et al. Inflammaging, hormesis and the rationale for anti-aging
1024		strategies. Ageing Res. Rev. 64, 101142 (2020).
1025	49.	Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of
1026		mortality due to COVID-19 based on an analysis of data of 150 patients from
1027		Wuhan, China. Intensive Care Med. 46, 846-848 (2020).
1028	50.	Fricke-Galindo, I. & Falfán-Valencia, R. Genetics Insight for COVID-19
1029		Susceptibility and Severity: A Review. Front. Immunol. 12, (2021).
1030	51.	Callahan, V. et al. The Pro-Inflammatory Chemokines CXCL9, CXCL10 and
1031		CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-

1032		Dependent Manner. Viruses 13 (6), 1062 (2021).
1033 1034 1035	52.	Alves, V. R. G. <i>et al.</i> Influenza A(H1N1)pdm09 infection and viral load analysis in patients with different clinical presentations. <i>Mem. Inst. Oswaldo Cruz</i> <b>115</b> , (2020).
1036 1037	53.	Im, S. J. <i>et al.</i> Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. <i>Nature</i> <b>537</b> , 417–421 (2016).
1038 1039 1040	54.	Zhao, Y., Shao, Q. & Peng, G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. <i>Cell. Mol. Immunol.</i> <b>17</b> , 27–35 (2020).
1041 1042	55.	Pieren, D. K. J. <i>et al.</i> Co-Expression of TIGIT and Helios Marks Immunosenescent CD8+ T Cells During Aging. <i>Front. Immunol.</i> <b>13</b> , (2022).
1043 1044	56.	Pereira, B. I. & Akbar, A. N. Convergence of Innate and Adaptive Immunity during Human Aging. <i>Front. Immunol.</i> <b>7</b> , (2016).
1045 1046 1047	57.	Galson, J. D. <i>et al.</i> Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures. <i>Front. Immunol.</i> <b>11</b> , (2020).
1048 1049	58.	Jia, C. <i>et al.</i> Immune repertoire sequencing reveals an abnormal adaptive immune system in COVID-19 survivors. <i>J. Med. Virol.</i> <b>95(1)</b> , (2023).
1050 1051	59.	Horvath, S. & Levine, A. J. HIV-1 Infection Accelerates Age According to the Epigenetic Clock. <i>J. Infect. Dis.</i> <b>212</b> , 1563–1573 (2015).
1052 1053 1054	60.	WHO. WHO Expert Committee on Physical Status : the Use and Interpretation of Anthropometry (1993 : Geneva, Switzerland) & World Health Organization. (1995).
1055 1056	61.	Corman, V. M. <i>et al.</i> Detection of 2019 novel coronavirus (2019-nCoV) by real- time RT-PCR. <i>Eurosurveillance</i> <b>25</b> ( <b>3</b> ), (2020).
1057 1058 1059	62.	Pelegí-Sisó, D., de Prado, P., Ronkainen, J., Bustamante, M. & González, J. R. <i>methylclock</i> : a Bioconductor package to estimate DNA methylation age. <i>Bioinformatics</i> <b>37</b> , 1759–1760 (2021).
1060	63.	Gupta, N. T. et al. Change-O: a toolkit for analyzing large-scale B cell

1061		immunoglobulin repertoire sequencing data. Bioinformatics 31, 3356-3358
1062		(2015).
1063	64.	Ye, J., Ma, N., Madden, T. L. & Ostell, J. M. IgBLAST: an immunoglobulin
1064		variable domain sequence analysis tool. Nucleic Acids Res. 41, W34–W40 (2013).
1065	65.	Lefranc, MP. IMGT, the International ImMunoGeneTics Information System.
1066		Cold Spring Harb. Protoc. 2011, D1006–D1012 (2011).
1067	66.	Heiden, J. A. Vander et al. AIRR Community Standardized Representations for
1068		Annotated Immune Repertoires. Front. Immunol. 9, (2018).
1069	67.	Gervasio, J. H. D. B. et al. How close are we to storing data in DNA? Trends
1070		Biotechnol. 42, 156–167 (2024).

#### 1072 Figure Legends:

1073 Figure 1: Early inflammatory profile of COVID-19 and Flu-Like syndrome patients. (a) 1074 Radar chart with the frequency of high mediator producers among individuals infected with 1075 COVID-19 from Belo Horizonte and São Paulo (n=36), Mild COVID-19 (n=20), Moderate 1076 COVID-19 (n=6) and Severe COVID-19 (n=10). (b) Differences in plasma mediator 1077 concentrations in individuals with different clinical forms of COVID-19. The population used 1078 for this analysis was the same as that used in Figure 1A. Samples were previously normalized, 1079 and outliers were excluded using the ROUT test. Mann-Whitney test was performed 1080 individually for each group. Lines were used to represent which groups were compared and 1081 asterisks to represent statistical significance ( $p \le 0.05$ , \*\* $p \le 0.01$ , \*\*\* $p \le 0.001$  or \*\*\*\*p < 0.0001). 1082 (c) Radar chart representing the frequency of high mediator producers among individuals 1083 infected with COVID-19, using individuals from Belo Horizonte and São Paulo (n=74), Flu-1084 Like Syndrome (n=38), Mild COVID-19 (n=42). (d) Comparative analysis of the concentration 1085 of each mediator among groups. Samples were previously normalized, and outliers were 1086 excluded from the data, using the ROUT test. Mann-Whitney test was performed individually for each group. Asterisks to represent statistical significance (p<0.05, \*\*p<0.01, \*\*\*p<0.001 or 1087 1088 \*\*\*\*p<0.0001). (e) Radar charts representing the frequency of high producers of plasma 1089 mediators in individuals from Belo Horizonte (n=46) with Flu-Like Syndrome (n=13), Mild 1090 COVID-19 (n=14), Hospitalized COVID-19 (n=12) and COVID-19 Progression (n=7). The 1091 Hospitalized COVID-19 group consists of individuals who were hospitalized with either 1092 moderate or severe COVID-19. (f) Analysis of the concentration of plasma mediators of 1093 individuals from Belo Horizonte with either COVID-19 or Flu-Like Syndrome (FS). The 1094 population used for this analysis was the same as that used in D. Asterisks represent statistical significance (\*p<0.05, \*\*p0.001, \*\*\*p0.001 or \*\*\*\*p0.0001). All groups presented in this 1095 1096 figure were matched by sex as well as age and they were composed of individuals at the initial 1097 stage of infection (1-4 days of symptoms).

1098

1099 Figure 2: Inflammatory profiles of adult and elderly people with Flu-like syndrome and 1100 COVID-19 living in endemic and in non-endemic areas for infectious diseases. (a) Radar chart representing the frequency of high producers of mediators among individuals from 1101 1102 Governador Valadares (n=56) with either Flu-Like Syndrome (n=30) or Mild COVID-19 1103 (n=26). (b) Comparative analysis of concentrations of plasma mediators in individuals with 1104 either Flu-like syndrome or Mild COVID-19. Samples were previously normalized, and outliers 1105 were excluded using the ROUT test. Mann-Whitney test was performed individually for each group. Asterisks represent statistical significance ( $p \le 0.05$ , \*\* $p \le 0.01$ , \*\*\* $p \le 0.001$  or 1106

37

\*\*\*\*p<0.0001). (c) Radar charts representing the frequency of high producers of mediators 1107 among individuals with COVID-19 in the adult (20-59 years) and elderly (over 60 years) age 1108 1109 groups in a non-endemic area (Belo Horizonte and São Paulo) - Adults (n=92) with Flu-Like 1110 Syndrome (n=45) and Mild COVID-19 (n=47) and elderly (n=19) with Flu-Like Syndrome 1111 (n=11) or Mild COVID-19 (n=8) and in an endemic area (Governador Valadares) - Adults (n=75) with Flu-Like Syndrome (n=39) and Mild COVID-19 (n=36) and elderly (n=11) with 1112 1113 Flu-Like Syndrome (n=5) and Mild COVID-19 (n=6) (d) Radar charts representing the 1114 frequency of high producers of CXCL9 among all individuals with Flu-Like Syndrome and 1115 COVID-19 in the adult and elderly age groups - (Adults n=40) with FS (n=14), Mild COVID-19 (n=15) and Hospitalized (n=11), elderly (n=26) with FLS (n=13), Mild COVID-19 (n=7) and 1116 1117 Hospitalized (n=6). (e) Comparative analysis of plasma concentrations of CXCL-9 in 1118 individuals with different clinical forms of COVID-19. Samples were previously normalized, 1119 and outliers were excluded using the ROUT test. Mann-Whitney test was performed 1120 individually for each group. Asterisks represent statistical significance ( $p \le 0.05$ , \*\* $p \le 0.01$ , \*\*\*p≤0.001 or \*\*\*\*p<0.0001). (f) Comparative analysis of plasma concentrations of CXCL-9 1121 1122 in individuals with different clinical forms of COVID-19. The population used is the same 1123 shown in Figure 2C. Samples were previously normalized, and outliers were excluded from the 1124 data using the ROUT test. Thus, the Mann-Whitney test was performed individually for each 1125 group. Lines were used to represent which groups were compared and asterisks to represent statistical significance (p≤0.05, \*\*p≤0.01, \*\*\*p≤0.001 or \*\*\*\*p<0.0001). All groups presented 1126 1127 in this figure were matched by sex as well as age and they were composed of individuals at the 1128 initial stage of infection (1-4 days of symptoms).

1129

1130 Figure 3: The senescence and exhaustion profile was significantly increased in individuals with moderate or severe COVID-19 compared to mild individuals in both CD8<sup>+</sup> and CD4<sup>+</sup> 1131 T cells. Patients were also stratified into 3 groups classified according to the severity of the 1132 1133 disease as mild (n=20), moderate (n=8) and severe (n=8). (a) Percentage of senescent and 1134 exhausted  $CD8^+$  T cells from individuals with mild, moderate and severe COVID. (b) The 1135 gating strategy was used to analyze markers related to senescence and exhaustion together 1136 within  $CD8^+$  T cells. Senescence cells are  $TIGIT^+$ ; exhausted are PD-1<sup>+</sup> and  $ICOS^+$ . (c) 1137 Percentage of senescent/exhausted  $CD8^+$  T cells from individuals with mild (20), moderate (8) 1138 and severe (8) COVID-19. Senescent/exhausted  $CD8^+$  T cells quantified by co-expression of CD57<sup>+</sup> and PD-1<sup>+</sup>, CD28neg and PD-1<sup>+</sup>, TIGIT<sup>+</sup> and ICOS<sup>+</sup>. KLRG1<sup>+</sup> marker may be present in 1139 1140 senescent and exhausted. (d) Representative flow cytometry of senescent/exhausted CD8<sup>+</sup> T 1141 cells, with the gate of interest showing a red square. (e) Percentage of senescent and exhausted 1142  $CD4^{+}T$  cells from individuals with mild, moderate and severe COVID. (f) Dot plots of

38

strategy was used to analyze markers related to senescence TIGIT<sup>+</sup>, CD57<sup>+</sup>, CD28neg and
KLRG1<sup>+</sup>, to exhaustion marker ICOS<sup>+</sup> and KLRG1<sup>+</sup> within CD4<sup>+</sup> T cells was used (red square).
\*p < 0.05, \*\*p < 0.01.</li>

1146 Figure 4: Analysis of immunoglobulin repertoires and of biological aging in patients with 1147 different clinical forms of COVID-19. (a) Graphical representation of clonal expansion of the 1148 100 most expanded clones in the repertoire of five individuals. The more intense the color, the 1149 more expanded the clone is. (b) Shannon entropy diversity was calculated using the diversity 1150 function of the 'vegan'package with the 100 most expanded clones for hospitalized individuals 1151 (n=20, Red), individuals with mild cases (N=19, Yellow), and negative individuals (n=6, Blue-1152 Cyan) from Belo Horizonte and Governador Valadares (only mild cases). Differences among 1153 groups were calculated using Mann-Whitney test and ROUT test to exclude outliers. Asteriscs 1154 represent statistical significance (\*p<0.01). (c) Repertoire maturity (divergence from germlinelike sequences) was calculated for the whole repertoire of hospitalized individuals (n=20, Red), 1155 1156 individuals with mild cases (N=19, Yellow), and negative individuals (n=6, Blue-Cyan) from 1157 Belo Horizonte and Governador Valadares (only mild cases). The ROUTE test was performed 1158 to remove outliers. (d) Accelerated aging was measured using eight different epigenetic clocks 1159 (Horvath; New Horvath; Levine; Hannum; BLUP; EN; Wu; TL) in unvaccinated COVID-19 1160 negative control individuals (n = 12) (Blue-Cyan), infected with COVID-19 Mild 9 (n = 9) 1161 (Yellow) and infected with Hospitalized COVID-19 (n = 17) (Red) without including endemic 1162 area. The y-axis shows the acceleration of epigenetic age after adjustment for cell type fractions 1163 (Residual Regression of Epigenetic Age Acceleration on Cell Type Fractions). The box plot 1164 represents the median, interquartile, minimum and maximum values of age acceleration (in 1165 years) determined for each group. One-way ANOVA and t-test were used to evaluate significant 1166 differences. Values of p < 0.05 were considered statistically significant (\*). (e) The same 1167 analysis as in Figure 4D was performed but including individuals from endemic areas. The 1168 population used includes unvaccinated COVID-19 negative control individuals (n = 12) (Blue-1169 Cyan), infected with COVID-19 Mild 9 (n = 18) (Yellow) and infected with COVID-19 1170 Hospitalized (n = 18) (Red). (f) Biological network of cytokines and cellular proteins of exhaustion and senescence in infected individuals with mild and severe COVID-19. Patients 1171 1172 who developed severe COVID-19 showed greater interactions with biomarkers of senescence 1173 and exhaustion in immune cells (including cytokines, chemokines, and cell surface markers) up 1174 to 4 days after infection, when compared to patients who developed the mild form of the 1175 disease. Blue thicker lines indicate positive correlations and red thicker lines negative 1176 correlations. The description of the codes present in the graph is in Supplementary Table 5. The size of the circles is proportional to their importance as hubs of connection. (g) A graphical 1177 1178 representation of the main biomarkers of aging (cytokines/chemokines, Ig repertoire, DNA

39

- 1179 methylation, cellular markers of exhaustion and senescence) illustrates the comparative
- 1180 differences between individuals with Mild and Severe COVID-19 comparing them with the
- 1181 same markers described for aged individuals. The size of the circles is proportional to the
- 1182 intensity of the parameter they represent.
- 1183 Tables

#### 1184 Table 1: Characterization of the study sample

	Flu-Like Syndrome (n=131)	COVID-19 Mild (n=127)	COVID-19 Moderate (n=18)	COVID-19 Severe (n=33)	P value
Age (years) (median; min/max)	38,0 (20±90)	39,0 (20±77)	49,0 (20±65)	*51,0 (31±68)	*p=0,147
Sex					
Female (%)	54,9	53,5	55,5	52,3	-
Male (%)	45,0	46,4	44,4	47,6	-
BMI (kg/m2) (median)	26,4	26,2	35,5	29,4	p>0,05
Symptoms onset (days) (median)	4,0	4,0	5,0	5,0	p>0,05
Comorbidities					
Hypertension (%)	17,5	14,1	44,4	42,4	-
Diabetes mellitus (%)	0,7	3,1	16,6	15,1	-
Respiratory diseases (%)	10,6	11,0	0,0	6,0	-
Others (%)	10,6	12,5	5,5	18,1	-
4405					

1185

1186 Data presented as median (min-max) and mean (± standard deviation). The Kruskal-Wallis and

1187 Dunn's tests were applied. \*Corresponds to the difference found for comparison between the

1188 other compared groups.

1189

1190

40

# 1192 Table 2: Characterization of the study sample by region

Belo Horizonte	Flu-Like Syndrome (n=76)	COVID-19 Mild (n=79)	COVID-19 Moderate (n=05)	COVID-19 Severe (n=14)	P value
Age (years) (median; min/max)	41,0 (20±79)	38,0 (20±68)	51,0 (31±64)	*53,0 (32±89)	*p=0,121
Sex					
Female (%)	53,9	50,6	20,0	28,5	-
Male (%)	46,0	49,3	80,0	71,4	-
BMI (kg/m2) (median)	26,1	26,0	33,5	28,4	p>0,05
Symptoms onset (days) (median)	4,0	5,0	2,0	4,0	p>0,05
Comorbidities					
Hypertension (%)	11,8	11,3	20,0	14,2	-
Diabetes mellitus (%)	2,6	3,7	20,0	14,2	-
Respiratory diseases (%)	10,5	11,3	0,0	0,0	-
Others (%)	7,8	13,9	0,0	7,1	-
Governador Valadares	Flu-Like Syndrome (n=44)	COVID-19 Mild (n=42)	COVID-19 Moderate (n=00)	COVID-19 Severe (n=03)	P value
Age (years) (median; min/max) Sex	35,0 (20±90)	39,0	-	45,0	p>0,05
Female (%)	47,7	59,5	-	33,5	-
Male (%)	52,3	40,4	-	66,5	-
BMI (kg/m2) (median)	26,6	26,2	-	22,3	p>0,05
Symptoms onset (days) (median)	3,0	4,0	-	3,0	p>0,05
Comorbidities					
Hypertension (%)	9,0	11,9	-	33,3	-
Diabetes mellitus (%)	0,0	0,0	-	0,0	-
Respiratory diseases (%)	4,54	4,7	-	0,0	-
Others (%)	0,0	2,3	-	33,3	-
São Paulo	Flu-Like Syndrome (n=11)	Covid-19 Mild (n=06)	Covid-19 Moderate (n=13)	Covid-19 Severe (n=16)	p value
Age (years) (median: min/max)	40.0 (23±69)	41.5 (28±50)	48.0 (20±56)	51.0 (31±64)	p>0.05
Sex		, ( ,	, ( ,	, ( ,	1 /
Female (%)	45.4	50.0	69.2	56.2	-
Male (%)	54.5	50.0	30.7	43.7	-
BMI (kg/m2) (median)	-	-	-	-	-
Symptoms onset (days) (median)	5.0	4.5	5.0	5.0	p>0.05
Comorbidities	- / -	7 -	- / -	- / -	
Hypertension (%)	9,9	0,0	38,4	37,5	-
Diabetes mellitus (%)	0,0	0,0	7,6	18,7	-
Respiratory diseases (%)	27.7	0.0	0.0	12.5	-
Others (%)	0.0	0.0	7.6	12.5	_
1102	-,-	-,-	- , -	,-	

1193

1194 Data presented as median (min-max) and mean (± standard deviation). The Kruskal-Wallis and

1195 Dunn's tests were applied. \*Corresponds to the difference found for comparison between the

1196 other compared groups.







d







